B. Riley Securities Maintains Buy on CymaBay Therapeutics, Raises Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities analyst Mayank Mamtani maintains a Buy rating on CymaBay Therapeutics (NASDAQ:CBAY) and raises the price target from $16 to $22.
September 08, 2023 | 4:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B. Riley Securities maintains a Buy rating on CymaBay Therapeutics and raises the price target from $16 to $22.
The news of B. Riley Securities maintaining a Buy rating on CymaBay Therapeutics and raising the price target from $16 to $22 is likely to have a positive impact on the stock price in the short term. This is because the raised price target indicates the analyst's increased confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100